36% of employers now cover GLP-1 drugs for both diabetes and weight loss, a survey found, a reading flat from the same figure in 2025. The number had gained 2 percentage points year-over-year in the prior period, rising from 34% in 2024 before the current plateau. The same survey reports that many employers are finding ways around expanding coverage, language that points to deliberate plan design rather than budget inaction.
Two-year trajectory
From 2024 to 2025, dual GLP-1 coverage climbed 2 percentage points, from 34% to 36%. The current survey period shows no further gain. A 2-point annual move followed by zero: the prior-year change looks increasingly like a one-cycle adjustment rather than the start of a sustained adoption trend.
The 36% reading means 64% of surveyed employers still do not cover GLP-1 drugs for weight-loss indications as of the current period. That share moved a combined 2 points across the entire two-year window the source covers, and the current reading does not narrow it further.
The survey tracks employers that cover GLP-1s for both diabetes and weight loss as a combined category. Plans covering the drug class only for metabolic or diabetes indications, and excluding obesity as a qualifying condition, fall outside the 36%.
The workaround signal
The survey's framing on the non-expanding majority is specific. Employers are finding ways around coverage expansion, the source states, a phrase that distinguishes intentional benefit design from passive non-adoption. A plan structured to route around a drug category differs from one that simply has not added it yet, and the survey's language treats them as distinct.
The source does not describe what those workarounds look like at the plan level, and no breakdown by employer size, sector, or plan type is provided.
The 64% question
A benefit category that added 2 percentage points in one year and zero in the next is not on a clear adoption curve, at least not in the data the survey provides. The flat reading, combined with the reported rise in workaround strategies, suggests a portion of the 64% is not on a path toward dual GLP-1 coverage. How large that portion is, the survey does not say.